Medlab Asia & Asia Health
The three-day Medlab Asia & Asia Health event ended on July 12, 2024 at the Queen Sirikit Convention Centre in Thailand. Wizbiotech highlighted the WIZ-A101 convenient immunoanalyzer, infectious disease quadriplex and bowel cancer early screening solutions, which attracted a large number of international professional visitors and received good feedback and business negotiations.
Since the first overseas market expansion, Wizbiotech has had in-depth exchanges and cooperation with customers and partners in many international exhibitions. With the continuous expansion of the market, more and more customers trust Wizbiotech, and its products have successively obtained EU CE, UK MHRA, Malaysia MDA certification, and have been exported to Germany, Italy, Spain, Finland, and other countries. Netherlands, Indonesia, Malaysia, Peru and other countries.
TheWIZ-A101 portable immunoanalyzerhas long been the device of choice in primary care Settings due to its cost-effectiveness, intuitive operating interface, easy to use flow, high availability and stability, and efficient data connectivity.
It can provide timely and accurate immunoassay results, help medical personnel to make rapid diagnosis and treatment plans, so as to improve medical efficiency, optimize medical resource allocation, and provide better medical services for patients. The exhibition, WIZ-A101 is still attracting attention, it brings convenience and efficiency so that more medical institutions and professionals see its importance and value in the medical industry. In the future, WIZ-A101 portable immunoanalyzer may become a leading product in primary medical care and contribute to the development and progress of primary medical care.
Quadruple screening for infectious diseases and early screening solutions for bowel cancer have also attracted wide attention. The four-joint test for infectious diseases can detect hepatitis B, hepatitis C, syphilis and AIDS at the same time, which improves the efficiency and accuracy of diagnosis and is of great significance for the prevention and control of infectious diseases. Bowel cancer early screening solution is through Cal, Fob, Tf three combined multi-indicator monitoring, more effectively promote bowel cancer risk screening, improve the success rate of treatment and patient survival, to provide more comprehensive health protection for individuals.
Benefit global customers and accelerate overseas market expansion. Wizbiotech's team will continue to participate in future international medical fairs and continue to promote advanced medical products and solutions. At the same time, Wizbiotech will strengthen cooperation with international partners to jointly promote the development of the medical industry and provide better products and services to customers worldwide. Thanks to all the visitors and partners who participated in Medlab Asia & Asia Health, Wizbiotech looks forward to meeting you again at future events.
